Summary
The response includes multiple mechanistic and product-manufacturing claims and an HBV testing/precautions-related assessment, but the provided label text only supports HBV screening/monitoring statements; no labeling support was provided for the mechanism, generic name, indication, or manufacturer.
Category Scores
Accurate Statements
Mavyret/HBV-related warning: HBV reactivation has been reported in HCV/HBV coinfected patients undergoing or had completed treatment with HCV direct-acting antivirals, and patients not receiving HBV antiviral therapy.
Section 5.1
Before initiating MAVYRET, test all patients for current or prior HBV infection by measuring HBsAg and anti-HBc.
Section 2.1 and Section 5.1
In patients with serologic evidence of HBV infection, monitor for clinical and laboratory signs of hepatitis flare or HBV reactivation during treatment and during post-treatment follow-up; initiate appropriate management as clinically indicated.
Section 5.1
Patient counseling: inform patients that HBV reactivation can occur in patients coinfected with HBV during or after treatment of HCV infection; advise patients to tell their healthcare provider if they have a history of HBV infection.
Section 7
Unsupported Statements
Mavyret's generic name is glecaprevir/pibrentasvir.
No provided label text supports the generic name mapping.
Mavyret is used to treat chronic hepatitis C virus (HCV) infection.
No provided label text includes indications.
Mavyret is a direct-acting antiviral (DAA) medication.
No provided label text defines or labels it as a DAA.
Mavyret works by inhibiting the hepatitis C virus NS3/4A protease.
No provided label text describes mechanism targets.
Mavyret works by inhibiting the hepatitis C virus NS5A protein.
No provided label text describes mechanism targets.
Glecaprevir inhibits the NS3/4A protease.
No provided label text describes component-specific mechanism.
Pibrentasvir inhibits the NS5A protein.
No provided label text describes component-specific mechanism.
By blocking these targets, Mavyret prevents the hepatitis C virus from multiplying and spreading in the body.
No provided label text supports this consequence/mechanism statement.
Mavyret is manufactured by AbbVie Inc.
No provided label text supports manufacturer attribution.
Contradictions
Important Omissions
The label includes boxed-warning cross-reference content emphasizing HBV testing/monitoring; the AI response did not explicitly address boxed warning labeling itself (only an HBV risk summary was included).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The only fully label-supported safety content present is HBV reactivation risk management (screening and monitoring). Unsupported mechanism/indication/manufacturer claims were not evaluated for clinical safety based on the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Several substantive claims (indication, DAA/mechanism targets, generic naming, and manufacturer) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported content in the provided sections (2.1/5.1/7 for HBV testing/monitoring and patient counseling). If other label sections are available (e.g., Indications and Usage; Drug Description/Mechanism; Dosage; Manufacturer info), align statements to those sections.